 "Vaccine")
Piramal Pharma Solutions (PPS), a part of Piramal Group that is engaged in contract development and manufacturing, has expanded the manufacturing capabilities of its Lexington (Kentucky, USA) facility.
PPS develops and manufactures sterile finished dosage forms at the Lexington site using the state of the art Isolator technology. The $25 million investment, which increases Piramal’s capacity and capabilities in manufacturing, is being rolled out in phases.
Phase-I, which is now complete, includes the installation of a new high-speed vial filling line, expansion of the state-of-the art laboratories, and associated utility support. The new filling line will double the capacity at Lexington, while enhancing efficiency and productivity. A large portion of the new capacity has already been committed to current clients to support their commercial product launches. The next phase of expansion, which includes expanding lyophilisation capability will begin immediately, and is expected to be operational by the end of 2018.
“At Piramal, we believe that geographical proximity is a key factor in ensuring customer delight. In keeping with this philosophy, we have now invested over $1.3 billion in North America and Europe. Pharma as a sector reverberates with our core values of ‘Knowledge-Action-Care’ and will continue to be an important area of focus for the group as we steadfastly pursue inclusive growth and generate value for all stakeholders globally,” said Ajay Piramal, chairman, Piramal Group.
With the completion of this first phase of expansion at Lexington, Piramal Pharma Solutions expects to support its customer product launches that address a broad range of adverse human conditions ranging from cancers to pre-term labour to rare childhood diseases. “It is our privilege to partner with customers as they seek to improve the quality of life of patients and we thank them for their continued trust and faith in us. Our world class talent at Lexington will be a key driver in ensuring that we sustainably delight our global customer base,” commented Vivek Sharma, CEO, Piramal Pharma Solutions.
